Comparative evaluation of pirarubicin and adriamycin in gynecologic cancer cell lines
Authors:
- Bernd-Uwe SevinBSBernd-Uwe Sevin
- Hervy AveretteHAHervy Averette
- James PerrasJPJames Perras
- Michael UntchMUMichael Untch
- Ronaldo RamosRRRonaldo Ramos
- Daniel DonatoDDDaniel Donato
- Manuel PenalverMPManuel Penalver
- 1 May 1992
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 45 (2) , 164-173
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- A phase i study of 4′-0-tetrahydropyranyladriamycin: Clinical pharmacology and pharmacokineticsCancer, 1990
- A phase II study of pirarubicin in malignant pleural mesotheliomaCancer, 1990
- Pirarubicin in advanced breast cancer: A French Cooperative phase II studyEuropean Journal of Cancer, 1990
- Phase II Study of Pirarubicin in Metastatic Breast CancerOncology Research and Treatment, 1990
- Phase I clinical trial and pharmacokinetic evaluation of 4?-0-tetrahydropyranyladriamycin (THP-adriamycin)Cancer Chemotherapy and Pharmacology, 1989
- Application of an ATP-bioluminescence assay in human tumor chemosensitivity testingGynecologic Oncology, 1988
- Phase I study of pirarubicinJournal of Cancer Research and Clinical Oncology, 1988
- Treatment of acute leukemia and malignant lymphoma with (2?R)-4?-O-tetrahydropyranyladriamycinCancer Chemotherapy and Pharmacology, 1987
- A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.Journal of Clinical Oncology, 1985
- Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinomaGynecologic Oncology, 1982